Starting from thioperamide, the first potent and selective H-3-recepto
r histamine antagonist, analogues have been synthesized and tested in
vitro on rat cerebral cortex to explore structure-activity relationshi
ps. The aim has been to design potent compounds which do not possess t
he thiourea group of thioperamide and which may have improved brain pe
netration. In a short series of open chain thiourea analogues, the opt
imum chain length for H-3-antagonist potency was found to be (CH2)(3).
Compounds derived from histamine and possessing an aromatic nitrogen-
containing heterocycle on the side chain amino group in place of thiou
rea show H-3-antagonist activity. Furthermore, when the heterocycle is
2-pyridyl, electron-withdrawing substituents (e.g. NO2, CF3, CO(2)Me)
in the pyridine 5-position increased potency. The synthesis of 4-[4(5
)-imidazolyl]piperidine and its conversion into the (trifluoromethyl)p
yridyl analogue 5b of thioperamide is described; however, 5b is not as
potent as thioperamide. Replacing imidazole by pyridine or substituti
ng imidazole on the remote N considerably reduced potency. Replacing t
he side-chain NH by S increased potency still further and the most pot
ent compound is 2-{[2-[4(5)-imidazolyl]ethyl]thio}-5-nitropyrodine (UC
L 1199) which has K-i = 4.8 nM.